Back to News
Market Impact: 0.4
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
Source: reuters.com
Corporate Guidance & OutlookHealthcare & BiotechProduct Launches
Novo Nordisk targets launches of more than five blockbuster drugs by 2030 and pipeline sales exceeding DKr150 billion ($23 billion) by 2035. CEO Mike Doustdar presented the long-term growth ambitions at the company’s Capital Markets Day in London, signaling a substantial expansion of its drug portfolio and revenue base.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
NVO0.72
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Tesla is ‘winding down’ production of the Cybertruck next year
- Needham reiterates Hold on Blink Charging stock after Q3 results
- Solventum stock price target raised to $100 by BTIG on results
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms